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Abstract
The hormone Insulin-like peptide 3 (INSL3) is a major secretory product of the Leydig cells from both fetal and adult testes.
Consequently, it is a major gender-specific circulating hormone in the male fetus, where it is responsible for the first phase
of testicular descent, and in the adult male. In most female mammals, circulating levels are very low, corresponding to only
a small production of INSL3 by the mature ovaries. Female ruminants are exceptional in exhibiting high INSL3 gene
expression by the thecal cells of antral follicles and by the corpora lutea. We have developed a specific and sensitive
immunoassay to measure ruminant INSL3 and show that, corresponding to the high ovarian gene expression, non-pregnant
adult female sheep and cows have up to four times the levels observed in other female mammals. Significantly, this level
declines during mid-pregnancy in cows carrying a female fetus, in which INSL3 is undetectable. However, in cows carrying a
male fetus, circulating maternal INSL3 becomes elevated further, presumably due to the transplacental transfer of fetal
INSL3 into the maternal circulation. Within male fetal blood, INSL3 is high in mid-pregnancy (day 153) corresponding to the
first transabdominal phase of testicular descent, and shows a marked dependence on paternal genetics, with pure bred or
hybrid male fetuses of Bos taurus (Angus) paternal genome having 30% higher INSL3 levels than those of Bos indicus
(Brahman) paternity. Thus INSL3 provides the first example of a gender-specific fetal hormone with the potential to
influence both placental and maternal physiology.
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Introduction
The peptide hormone Insulin-Like Peptide 3 (INSL3; formerly
relaxin-like factor, RLF) belongs to the relaxin-insulin family of
peptide hormones [1,2]. It evolved as a paralogue of relaxin
accompanying mammalian emergence [3], and like relaxin
appears to subserve ‘‘neohormone’’ functions [4], the most
important of which is to regulate the first transabdominal phase
of testicular descent in the embryo during mid-gestation [2]. It is
produced in large quantities by the Leydig cells of both the fetal
and adult testes, and gives rise to substantial circulating INSL3
concentrations in the blood of adult male mammals (rat, 5 ng/ml
[5]; mouse, 2 ng/ml [5]; human, 0.8–2.5 ng/ml [6–8]; rhesus
monkey, 1.5 ng/ml (unpublished)). To date there is very little
information about INSL3 peptide levels within the fetus. We have
shown in human pregnancies that amniotic fluid contains
substantial amounts of INSL3 of fetal origin, which can only be
detected in male fetuses and has its maximum at weeks 12–16 of
gestation at the time of the transabdominal phase of testicular
descent [9]. In preliminary studies in rats, we have also shown that
male fetuses in the second half of gestation have similar amniotic
INSL3 concentrations to those measured in human amniotic fluid,
and that blood from such male fetuses contained INSL3
concentrations comparable to adult males (Ivell, Anand-Ivell &
Barthol, unpublished). In all cases INSL3 was below the level of
detection in fluids from female fetuses.
In the adult female mammal circulating INSL3 concentrations
are much lower than in the male (rat, 0.08 ng/ml [5], mouse,
0.05 ng/ml [5]; human, 0.05–0.10 ng/ml [6,7,10]), and presum-
ably reflect local production of INSL3 within the ovary [2]. Here
immunohistochemical and mRNA evidence supports a production
by the theca layer of smaller antral follicles, as well as by corpora
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are found to have almost double the normal circulating levels of
INSL3 [10,15], which appears to be associated with the number of
cystic follicles [15].
Within this context ruminants appear to be special, with the
ovaries expressing very high levels of INSL3 mRNA both in antral
follicles and in the corpus luteum [11,16]. It has been speculated
that in some way the high INSL3 expression might be
compensating for the fact that in ruminant evolution the closely
related gene for relaxin has been lost [11], though there is as yet no
functional evidence to support this idea. As in other species,
INSL3 mRNA is expressed by the theca interna cells of antral
follicles and appears to be negatively regulated by high LH [16],
although it is also expressed after luteinisation within the corpus
luteum. Across the estrous cycle, luteal INSL3 mRNA levels rise
from early to mid cycle and then decline again at luteolysis unless
pregnancy occurs, when INSL3 mRNA continues to rise until mid
gestation and remains elevated until shortly before birth [16].
Although peptide INSL3 has been successfully extracted from
bovine testis [17], to date there is no information about INSL3
levels in the circulation of any ruminant, especially within females,
which might offer clues to the high level of expression in the
ovaries of sheep and cows. We have successfully developed a new
time-resolved fluorescence immunoassay (TRFIA) to directly
detect INSL3 in the blood and body fluids of ruminants. We
have used this new assay to measure circulating INSL3 firstly
across the estrous cycle in synchronized gravid and non-gravid
sheep, and secondly in both maternal and fetal bloods through
gestation from a controlled experiment with Bos taurus and B.indicus
cows. Not only are female circulating INSL3 concentrations
significantly higher than in other non-ruminant species, but during
gestation we see for the first time for any species and hormonal
factor, clear evidence of a fetal gender-specific elevation in
maternal serum INSL3, most likely derived by placental transfer of
INSL3 from the male fetus to the mother. In addition, our bovine
model with purebred and reciprocal hybrid fetuses shows a highly
significant effect of fetal genetics on fetal INSL3 production, which
is not simply reflecting the known influences of heterosis on fetal
growth.
Results
INSL3 concentration during the estrous cycle and early
pregnancy in ewes
Blood samples were systematically collected at three time points
(days 5, 12, and 17) from the 17-day cycle of 6 gravid and 4 non-
gravid synchronized ewes. No significant differences in circulating
INSL3 concentration were observed for any day between gravid
and non-gravid sheep (Fig.1A), although in the pregnant ewes the
increase in INSL3 concentrations on day 12 compared to day 5
approached significance (P=0.06), and values were close to being
significantly different between gravid and non-gravid animals
(P=0.07) on day 17. Peptide levels appear to reflect what is known
of the luteal INSL3 mRNA expression with levels generally elevated
from day 5 through to day 17, especially in the gravid cycles. The
comparable circulating progesterone concentrations are indicated
in Fig.1B, where the expected significant difference at luteolysis can
be observed between gravid and non-gravid ewes. A comparison of
all INSL3 values from days 5 and 12 (thus excluding those
undergoing luteolysis or not at day 17) against the corresponding
levels of circulating progesterone (Fig.1C) showed a significantly
positive relationship (P,0.01) reinforcing the luteal origin of the
circulating INSL3. It is to be noted that whereas all INSL3 values
from gravid animals showed a consistent 15 to 223% increase
between days 5 and 12, corresponding values from the 4 non-gravid
animals were more variable, ranging from 253% to +73%.
Circulating INSL3 concentrations during pregnancy in
cows
Blood samples were collected from heifers of the Angus (B.taurus)
and Brahman (B.indicus) breeds at the time of synchronized
insemination (day 0) and were considered representative of the
non-gravid cow. There was no significant difference in peripheral
INSL3 concentration (mean 6 SEM) between the two breeds
(Angus: 0.17 6 0.02 ng/ml, n=10; Brahman: 0.1860.01 ng/ml,
n=10), with values very similar to those observed in sheep
(Fig.1A). This lack of maternal breed difference did not change
throughout gestation, and thus in subsequent analyses maternal
genotype is combined (Fig.2). Plotting maternal INSL3 concen-
trations across gestation showed little variation, unless fetal gender
is taken into account (Fig.2). Following an initial small decline in
circulating maternal INSL3 (p,0.05 for animals carrying a male
fetus), levels remained around the day 0 values until the end of the
first trimester (day 99). At mid-gestation (day 153), cows carrying a
male fetus showed significantly (p,0.001) higher maternal INSL3
as compared with cows carrying a female fetus, where maternal
INSL3 concentrations declined to levels significantly below day 0
values (p,0.01). Consequently, at day 153, maternal INSL3
concentration clearly distinguishes the gender of the fetus
(p,0.001). This gender-specific effect on maternal INSL3 levels
appears to be maintained until term (day 277). Because of the
relatively high variance in maternal INSL3 concentration, we were
unable to detect any effect of fetal genetics in those cows carrying
male fetuses (not shown).
Fetal INSL3 concentrations, gender and genetics
In addition to maternal bloods, we also analysed fetal blood
from day 153 pregnancies for INSL3 concentration. Without
exception, all female fetuses had undetectable (,0.02 ng/ml)
levels of INSL3 (data not shown). This was also true for the small
number of female fetuses analysed at term (day 277). In contrast all
male fetuses indicated substantial circulating concentrations of
INSL3 (range 1–5 ng/ml). There was a pronounced effect of fetal
genetics on the circulating concentration of INSL3 within these
male fetuses (Fig.3). Purebred Angus fetuses as well as the
Brahmanmaternal x Anguspaternal hybrids had significantly higher
serum INSL3 concentrations compared to either purebred
Brahman or Angusmaternal x Brahmanpaternal hybrids (Fig.3). The
30 percent increase in the INSL3 plasma concentration of fetuses
sired by Angus bulls indicates a strong paternal genetic effect on
INSL3 in the fetus. It should be noted that we found no significant
correlation between fetal INSL3 and maternal INSL3 concentra-
tions in cows carrying a male fetus (data not shown).
Heterosis or hybrid vigour is a well established biological
phenomenon where the phenotype of F1 hybrids is superior to the
parental phenotype. In the present study, there was no obvious
heterosis effect in terms of fetal weight at day 153 (Fig.3), with
purebred Angus and Angusmaternal x Brahmanpaternal fetuses being
significantly heavier than the Brahmanmaternal x Anguspaternal and
purebred Brahman fetuses. In fact, the Brahmanmaternal x
Anguspaternal hybrid was intermediate in weight between the two
purebred parental breeds. Since INSL3 appears to be uniquely a
product of the fetal testis, we investigated if the genetic effects on
fetal INSL3 concentration could be due to altered growth and
development of the fetal testes. However, examination of fetal
testis weights showed the opposite trend, with fetuses of purebred
genetics having similar testis weights, and the reciprocal hybrids
having heavier (Angusmaternal x Brahmanpaternal) or lighter
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although only the differences between hybrids were statistically
significant (Fig.3). Thus neither fetal weight nor testis weight can
account for the marked differences in INSL3 concentrations of
fetuses with different genetics. A further factor that might
contribute to the differences in fetal INSL3 concentration is the
amniotic fluid volume. We have previously shown that early
second trimester human amniotic fluid contains substantial
concentrations of INSL3 [9] presumably derived from the fetal
circulation at a time when fetal vasculature and tissues are still
relatively permeable. Fetal INSL3 concentration might then reflect
a dilution effect caused by a genetics-dependent difference in
amniotic fluid volumes and/or fetal weight. However, the actual
data again show that this is not the case (Fig.3). There is no clear
inverse relationship of gestational volume with fetal INSL3
concentration, and even though there is an apparent inverse
relationship between INSL3 levels and total amount of fetal fluid
volume, the genotype-dependent differences in the latter are too
small to account for the large changes in fetal serum INSL3
concentration.
Figure 2. Circulating maternal concentrations of INSL3 in pregnant Brahman and Angus cows (combined since no significant
difference between breeds at any time-point). Filled bars represent cows carrying a male fetus, open bars those carrying a female fetus. The
cross-hatched bar (left) represents cows at the time-point of insemination. N values are indicated in parentheses below the bars. Statistical
significance using both t test and Neumann-Keuls post hoc test are as indicated (ns, not significant).
doi:10.1371/journal.pone.0019821.g002
Figure 1. Circulating INSL3 (A) and progesterone (B) concentrations in gravid (filled bars; N=6) and non-gravid (open bars; N=4)
sheep (means ± SD). Statistical significance is shown only where P,0.05. (C) Correlation (r=0.4; P,0.05) of INSL3 and progesterone values for
samples collected on days 5 and 12 only, excluding day 17 (luteolysis).
doi:10.1371/journal.pone.0019821.g001
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Previous studies atthemRNAlevelhaveindicatedthat withinthe
female ruminant the ovary represents by far the major source of
INSL3 [11,16]. Northern blot analysis indicates very strong signals
in the corpus luteum of the cycle and pregnancy, with similar strong
signals also deriving from primary preparations of follicular theca
cells. By weight, the corpora lutea are likely to be the major ovarian
source of INSL3 peptide, rather than the theca interna, although to
date this has not yet been analysed directly. All other tissues
examined, including oviduct, endometrium and myometrium from
the cycle and pregnancy, caruncles, cotyledons, amnion and
chorion, all from term pregnancies, thyroid gland, hypothalamus,
heart, lung, cerebellum, cerebral cortex, pituitary and pineal glands,
spleen, liver and adrenal gland were all negative for INSL3 mRNA
by northern analysis, with only very weak signals appearing
sporadically from some tissues following the use of RT-PCR and
product visualization by radioactive hybridization, which is a highly
sensitive detection technique [16]. Reflecting this expression
pattern, we see high levels of circulating INSL3 (ca. 0.1 to
0.2 ng/ml) throughout the estrous cycle in both sheep and cows.
This is approximately twice to four times the circulating levels seen
in healthy women [10,15]. Interestingly, if the INSL3 concentra-
tions from days 12 and 17 are combined, then these do show a
significant difference (P,0.05) between gravid and non-gravid
ewes. Combining INSL3 and progesterone values for individual
ewes on day 17 provided a pregnancy index with 100% positive and
100% negative predictive value. This now needs to be validated for
a larger sample size.
In cows, non-pregnant circulating INSL3 concentrations appear
to be maintained during the first trimester of pregnancy, with
possibly a small decline at day 48. In dams carrying female fetuses,
which do not themselves express INSL3, the circulating maternal
INSL3 concentration then declines to low values (ca. 0.1 ng/ml)
by mid-gestation, which appear to be maintained until term. This
is of interest since our earlier studies had shown that luteal levels of
mRNA are maximal at this time [16]. This would suggest that
other post-transcriptional mechanisms such as peptide production,
secretion rates, serum half-life or luteal blood flow are regulating
the peripheral INSL3 concentration. It is well established that, in
terms of oxytocin and progesterone production, the bovine corpus
luteum has markedly reduced influence in the latter half of
gestation (except possibly at term), when these functions are largely
taken over by the pituitary and placenta, respectively [18].
This situation is quite different for dams carrying a male fetus.
For the first time for any truly fetal hormone (excluding
trophoblast-derived hCG or interferon-tau), we can detect
significantly increased levels of INSL3 in maternal serum at
mid-pregnancy (day 153), which must be derived uniquely from
the male fetus. From the results on female fetal blood, as well as
earlier results on human amniotic fluid [9], we know that there is
no detectable contribution of INSL3 to maternal serum from the
female fetus, nor from the placenta. The results presented here
suggest that the male fetus is contributing ca. 0.2 ng/ml INSL3 to
the maternal circulation, and hence also to all maternal organs
including the Placenta materna. This fetal signal appears to be
maintained throughout the latter half of gestation. Whilst there is
always the possibility that this gender-specific rise in maternal
INSL3 could be caused by an indirect fetal effect on the ovary, this
appears highly unlikely in view of the obvious lack of any other
gender-specific fetal factor which might stimulate this effect, and
the much more obvious cause of a trans-placental transfer of
INSL3 directly from the male fetus.
Direct measurement of INSL3 in mid-term fetal blood indicates
that the male fetus is producing large amounts (range 1–5 ng/ml)
of the gonadal peptide into the fetal circulation at this time,
concomitant with its role to stimulate gubernacular development
and the first transabdominal phase of testicular descent [19].
Surprisingly, there is a marked effect of fetal genetics on fetal
INSL3 production, with the paternal genetics determining INSL3
levels. Fetuses with Bos taurus (Angus) paternal genetics show
approximately 30% higher INSL3 levels than fetuses with B.
indicus (Brahman) paternal genetics. We have previously noted
marked genetic effects on adult INSL3 concentrations amongst
Figure 3. INSL3 concentration in fetal venous blood, fetal weight, fetal testis weight, and calculated total fetal fluids on day 153 of
pregnancy, and sorted by fetal genetics, as indicated. Amaternal indicates an Angus (B. taurus) dam, Bpaternal a Brahman (B. indicus) sire, etc.
doi:10.1371/journal.pone.0019821.g003
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on bovine fetal INSL3 production is independent of testis size, as
well as of fetal size and the amount of fetal fluid, and thus does not
appear to be an aspect of any heterosis effects in this experiment.
This is consistent with preliminary analysis of pregnancy
parameters [20] which revealed that at mid-gestation (day 153)
hybrids did not show heterosis in fetal size, but were intermediate
to both parental genetics. Taken together, these results imply that
paternal genetics is determining the level of INSL3 independently
of the relative sizes of fetal testis, total fetal weight or amount of
fetal fluid. It is noteworthy in this context that the Y chromosomes
of Bos taurus (e.g. Angus) and Bos indicus (e.g. Brahman) show
considerable structural and size differences [21] and that Y
chromosome substitution in model organisms has revealed effects
on the expression of thousands of genes, presumably mediated by
epigenetic effects of transposons [22]. The current experiments did
not involve embryo transfer, and so we are not able to analyse
what effects might be observed when pure-bred fetuses (e.g.
Brahmanmaternal 6 Brahmanpaternal) develop in the alternative
maternal genotype (e.g. Angusmaternal 6 Anguspaternal), though it
might be difficult here to distinguish effects of maternal genotype
from those consequent upon an IVF protocol [23].
There is some evidence to suggest that there may be a breed
difference in cattle in the incidence of cryptorchidism [24].
Though Brahman cattle were not included in this study, it is
therefore possible that bulls of different breeds may have differing
levels of INSL3 production, as in rats [5]. A study to examine this
aspect of INSL3 physiology is planned.
The results presented here imply that INSL3 from the male fetus
is able to cross the placenta and enter the maternal bloodstream.
Whilst there is limited evidence supporting the possible expression of
INSL3 itself within the cytotrophoblast in women [25], deer [26]
and dogs [27], this is evidently not of sufficient amount to influence
the maternal circulation in ruminant pregnancies carrying a female
fetus. Conversely, it is interesting to note that in cows carrying a
female fetus the maternal INSL3 contribution, presumably of
ovarian origin, significantly (p,0.002) declines between days 99 and
153. This could be interpreted as indicating that the maternal
INSL3 observed in the non-pregnant cow might otherwise also be
able to cross the placenta in the direction of the fetus, where it could
induce some kind of ovarian descent or other malfunction, as has
been demonstrated in female mouse fetuses transgenically expressing
the Insl3 gene [28]. There are still too few data available to know
whether such placental transport would be a general feature in
mammals, or whether it is a special property of the ruminant
placenta.
Since maternal circulating INSL3 remains unchanged in
pregnant women, whether carrying a male or a female fetus
(Anand-Ivell & Ivell, unpublished), it would appear most likely that
any more general mammalian function for fetal INSL3 is likely to
be confined to the feto-placental unit. INSL3 has been shown to be
the unique ligand in the low nanomolar range of the RXFP2
receptor, previously called LGR8 [29,30]. It has also been shown
in vitro to be able to activate the receptor, RXFP3, for the
neuropeptide relaxin-3, but only at very high, micromolar
concentrations [31]. Thus in order to discuss what role a fetal
gender-specific hormone like INSL3 is having during gestation,
beyond its known role in testicular descent [2], we need to
examine where RXFP2 receptors are expressed within the uterus
and placenta. In the human and rat, RXFP2 appears to be
expressed only in the myometrial layers [32,33] but not within any
placental tissue [34]. Within human myometrial cells from the
menstrual cycle, RXFP2 was shown not to respond in a typical Gs-
or Gi-linked fashion [33] suggesting that its role is likely to be more
subtle. However, Vodstrcil and colleagues [32] were able to show
that myometrial RXFP2 receptor mRNA was up-regulated in rat
gestation by an IUGR intervention, supporting a role for this
INSL3-RXFP2 system in the feto-placental dialogue. Further-
more, in women undergoing first trimester amniocentesis and later
diagnosed with preeclampsia [9], INSL3 concentrations in
amniotic fluid were significantly elevated compared to normal
controls at a time when the placenta was evidently not developing
correctly, even though preeclamptic symptoms would first become
evident months later. In pregnant cows at least this gender-specific
elevation of circulating INSL3 is likely to have a positive effect on
bone density, reflecting the recent discovery in humans and mice
that the INSL3-RXFP2 system is significantly involved in bone
metabolism [35].
For humans, there is some evidence for fetal gender-specific
effects on the incidence of preterm labour and preeclampsia (both
more likely for male fetuses; [36,37]), whereas IUGR appears to be
marginally more likely for female fetuses [37]. Such data are,
however, controversial [38]. It is also reported that there is a fetal
gender-specific influence on maternal hCG (increased when
carrying a female fetus) and MSAFP (decreased when carrying a
female fetus) [39]. Such findings would support an influence by a
male- or female- specific fetal factor on placental function. Since
fetal steroids do not vary sufficiently between genders to
satisfactorily account for such changes, INSL3 would present
itself as a likely candidate in the feto-placental dialogue. More
research is now required to explore this possibility.
In conclusion, therefore, we have shown that ruminants express
moderately high levels of circulating INSL3 throughout the estrous
cycle and pregnancy, but that this level increases significantly
during mid-gestation only when the cow is carrying a male fetus.
Materials and Methods
Sheep
We used 10 Merino ewes aged 2.5 years and weighing
52.361.5 kg with a condition score of 2.860.1 (scale from 0:
emaciated to 5: obese [40]) that were selected from a larger study.
All ewes grazed dry summer pasture predominantly comprising
barley grass and capeweed without a supplement. Sponges
containing medroxy-progesterone (CronogestH, Intervet, Australia)
were inserted for 14 days and 200 IU of eCG (FolligonH, Intervet,
Australia) injected at sponge removal, two days before artifical
insemination (AI, Day 0). Ewes were housed in a shed without food
and water for 24 h before AI, performed 49–57 hours after sponge
removal. Semen from Texel rams that had been evaluated (mass
motility .4; density .4) and pooled, was used for AI. The
ejaculates were diluted 1:3 with UHT skim milk and the
insemination volume was adjusted to give a dose of 200 million
sperm per ewe. Blood was sampled after 12 h fasting on Days 5 (day
of embryo arrival in the uterus), 12 (around maternal recognition of
pregnancy) and 17 (follicular phase in non-pregnant ewes) after AI.
Blood plasma was harvested and stored at 220uC until assayed for
progesterone and INSL3. Ovulation rate and pregnancy were
diagnosed by transrectal ultrasonography using a 7.5 MHz linear
array transducer on Days 10 and 30. Only ewes that had a single
ovulation were selected for this study. One ewe had high a
progesterone concentration on day 17, but later gave no positive
signs of pregnancy at ultrasound on day 30, indicating early
pregnancy loss. For this study this animal is included as pregnant.
Experimental procedures were approved by the Animal Ethics
Committee of the University of Western Australia (no. RA/3/100/
534), according to the recommendations of the Australian National
Health & Medical Research Council.
Ruminant INSL3
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kit(DiagnosticSystems LaboratoriesInc, Webster,TX)asdescribed
elsewhere [41]. The limit of detection was 0.4 ng/mL. For low
(0.9 ng/mL) and high (10.4 ng/mL) progesterone concentrations,
the intra-assay coefficients of variation were 2.6% and 4.1%, and
inter-assay coefficients of variation 5.7% and 11.1%.
Cattle and fetuses
We used animals of the Angus and Brahman breeds to study
maternal and fetal INSL3 levels during gestation. The two
breeds represent the genetics of two subspecies with taurine (Bos
primigenius taurus)a n dz e b u i n e( B. p. indicus) phenotype, respec-
tively, found in domestic cow and commonly referred to as Bos
taurus and Bos indicus [42]. Angus and Brahman females which
had not given birth previously and were approximately 16–
20 months of age received standard commercial estrous cycle
synchronization (e.g. http://www.absglobal.com/aus/resources/
beef-resources/synchronization-programs---cue-mate-1/). We used
Cidirol - Heat Detection & Timed Insemination (HTI) and Cidirol -
Timed Insemination (TI). Briefly this consisted of an initial injection
of 1 ml of 1 mg/ml estradiol benzoate (Cidirol, Genetics Australia
Co-operative Ltd., Bacchus Marsh, Australia) and insertion of a
progesterone-releasing vaginal insert (Eazi-Breed CIDR, DEC
International, Hamilton, New Zealand). The vaginal inserts were
removed after 7–9 days and heifers injected with 2 ml of a
prostaglandin analogue (0.26 mg of cloprostenol sodium/ml (Estru-
mate), Schering-Plough Animal Health, Baulkam Hills, Australia).
Estrus detection devices (Kamar, Agrigene, Wangaratta, Australia)
were placed on all animals. In HTI, animals that showed estrus two
days later were inseminated while animals not in estrus received an
additional 0. ml injection of estradiol benzoate and were inseminated
24 h later. In TI, animals received 0.7 ml estradiol benzoate the day
after removal of vaginal inserts and were inseminated 24 h later.
Synchronization/insemination was repeated in HTI and TI with
estradiol benzoate injection of all animals after removal of vaginal
inserts, followed by a final round of insemination and natural
breeding in HTI animals without further synchronization measures.
We used Angus and Brahman paternal genetics in HTI and TI.
Animals were pregnancy tested by ultrasound scanning.
Blood samples were obtained on Days 0, 48, 99, 153 and 277
of gestation. Day 277 was considered term as gestation length in
the cow ranges from Day 273 to Day 292 [43]. Fetal blood
samples were collected from the umbilical cord (Day 153) after
removal of the fetus from the uterus in an abattoir, or by jugular
vein puncture (Day 277) after delivery of the calf by caesarian
section. Serum was stored frozen at 280uC until INSL3 analysis.
The amount of fetal fluids was estimated by subtracting the
combined fetal, placental, and washed uterine weights from the
weights of the intact gravid uteri prior to dissection. Gender of
Day 48 concepti was determined by SRY typing using PCR with
S4B primers [44], and of Day 99 fetuses by ultrasound scanning.
All procedures involving cattle in this study were approved by
The University of Adelaide Animal Ethics Committee (nos. S-
094-2005 and -2005A).
INSL3 Assay development, validation and characteristics
Bovine INSL3 was generously synthesized and made available
by Dr John Wade of the Florey Institute, University of Melbourne,
according to the sequence A-chain: ATAINPARHCCLSGCTR-
QDLLTLCPH, B-chain: QEAPEKLCGHHFVRALVRLCGGP-
RWSSEEDG, predicted from the cloned cDNA sequence [11].
This is essentially confirmed at the peptide level by Bullesbach &
Schwabe [17] who, however, also identified molecules with a
further extension at the C-terminus of the B-chain. NMR was used
to confirm that the A–B heterodimer was in the correct native
conformation (Dr J.D. Wade, personal communication). Polyclon-
al antibodies were raised in rabbits against this A–B heterodimer
using conventional techniques and used to generate a robust time-
resolved fluorescence immunoassay (TRFIA) exactly as previously
described for the human INSL3 assay [7,8]. As tracer for the
assay, bovine A–B heterodimer was labelled with (Eu
3+) chelate
exactly as described previously. Following assay optimization,
assay detection range was from 0.02 to 20.0 ng/ml bovine INSL3.
Within-assay c.o.v. was ,2% across the range and ,0.5% in the
mid-range, between-assay c.o.v. was consistently ,10%. Repeated
freeze-thaw cycles as well as experiments to test the effects of
storage for different periods at room temperature, 4C or 20C,
showed that bovine A–B heterodimeric INSL3 is remarkably
stable with .93% recoveries at all times. This assay is highly
specific for ruminant INSL3, with #0.1% cross-reactivity to
human and rat INSL3, and no detectable cross-reactivity to
porcine relaxin, IGF1 or insulin.
Statistical analysis. All data were analysed employing
GraphPad Prism 5.0 software using 2-way ANOVA with
Neumann-Keuls post hoc test of significance. Some data were
additionally analysed using a standard t test. Differences were
considered significant at P,0.05.
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